Tremelimumab-actl

{
  "id": "MLC-T-ONC-017311",
  "term": "Tremelimumab-actl",
  "field": "Oncology and biomedicine",
  "definition": "A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab-actl binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.",
  "synonyms": [
    "tremelimumab",
    "ticilimumab",
    "anti-CTLA4 human monoclonal antibody CP-675,206"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tremelimumab-actl/"
}